Open a free Demat account & get ₹500 in stocks.Claim
Nifty 5025,299.351.02%H 25,384.8 · L 25,142.95as of 12 Nov, 3:31 PM IST|Sensex81,911.010.99%H 82,325.61 · L 81,576.15as of 12 Nov, 3:32 PM IST|Bank Nifty61,518.52.97%H 61,545.85 · L 60,723.1as of 12 Nov, 3:31 PM IST|USD / INR₹94.030.01%H ₹94.03 · L ₹94.03upd. 8:17 AM IST|Gold Intl (10g)₹1,18,280.060.7%H ₹1,18,515.86 · L ₹1,17,270.33upd. 8:14 AM IST|Silver Intl (1kg)₹1,52,456.570.73%H ₹1,53,348.39 · L ₹1,50,763.62upd. 8:14 AM IST|Crude WTI₹8,323.540.25%H ₹8,361.15 · L ₹8,278.4upd. 8:14 AM IST|Bitcoin₹65,99,7234.59%H ₹67,51,291.7 · L ₹64,48,154.3upd. 8:16 AM IST|Ethereum₹1,86,9583.02%H ₹1,89,777.89 · L ₹1,84,138.11upd. 8:16 AM IST|Nifty 5025,299.351.02%H 25,384.8 · L 25,142.95as of 12 Nov, 3:31 PM IST|Sensex81,911.010.99%H 82,325.61 · L 81,576.15as of 12 Nov, 3:32 PM IST|Bank Nifty61,518.52.97%H 61,545.85 · L 60,723.1as of 12 Nov, 3:31 PM IST|USD / INR₹94.030.01%H ₹94.03 · L ₹94.03upd. 8:17 AM IST|Gold Intl (10g)₹1,18,280.060.7%H ₹1,18,515.86 · L ₹1,17,270.33upd. 8:14 AM IST|Silver Intl (1kg)₹1,52,456.570.73%H ₹1,53,348.39 · L ₹1,50,763.62upd. 8:14 AM IST|Crude WTI₹8,323.540.25%H ₹8,361.15 · L ₹8,278.4upd. 8:14 AM IST|Bitcoin₹65,99,7234.59%H ₹67,51,291.7 · L ₹64,48,154.3upd. 8:16 AM IST|Ethereum₹1,86,9583.02%H ₹1,89,777.89 · L ₹1,84,138.11upd. 8:16 AM IST|
0%
IPOsBreaking

Symbiotec Pharmalab Plans ₹150 Crore IPO for Debt Repayment, Expansion

Arth Vani DeskPublished: 1 min read
Symbiotec Pharmalab Plans ₹150 Crore IPO for Debt Repayment, Expansion

Source: Economictimes

Arth Insight · What this means for your wallet

Immediate action
Evaluate if investing in Symbiotec Pharmalab's IPO aligns with your risk tolerance.
  • This IPO offers a potential high-risk, high-reward investment opportunity for your savings.
  • Investing carries the risk of losing some or all of your capital if the company's shares underperform.
  • It could be a chance to diversify your investment portfolio into the specialized pharmaceutical API sector.
Recommended for you
Track live & upcoming IPOs
View IPO Center
Listen to this article
AI voice · Podcast mode
Get IPO & market alerts free on Telegram / WhatsApp
AI Summary

Symbiotec Pharmalab, a global leader in corticosteroid and steroidal-hormone APIs, is planning an Initial Public Offering (IPO) to raise ₹150 crore. The funds are earmarked for repaying existing debt and expanding its operational capabilities. The company has shown consistent revenue and EBITDA growth, primarily driven by its international market presence, particularly in Europe.

Key Highlights
  • ▸Symbiotec Pharmalab is launching an IPO to raise ₹150 crore.
  • ▸The funds will be used to repay debt and expand operations.
  • ▸The company is a global leader in corticosteroid and steroidal-hormone APIs.
  • ▸It has shown steady revenue and EBITDA growth, primarily from international markets.
Key Takeaways
  • ✓Symbiotec Pharmalab is launching an IPO to raise ₹150 crore.
  • ✓The funds will be used to repay debt and expand operations.
  • ✓The company is a global leader in corticosteroid and steroidal-hormone APIs.
  • ✓It has shown steady revenue and EBITDA growth, primarily from international markets.

Symbiotec Pharmalab, a prominent player in the Active Pharmaceutical Ingredient (API) sector, is set to launch an Initial Public Offering (IPO) aiming to raise ₹150 crore. This strategic move is intended to bolster the company's financial health by repaying outstanding debt and fueling its expansion initiatives.

The company holds a significant global position, particularly recognized for its leadership in the production of corticosteroid and steroidal-hormone APIs. These specialized pharmaceutical ingredients are crucial components in various medications, underscoring Symbiotec Pharmalab's importance in the global healthcare supply chain.

Global Footprint and Financial Performance

A substantial portion of Symbiotec Pharmalab's revenue is generated from international markets, with Europe identified as a key contributor. This global reach highlights the company's competitive edge and its ability to cater to diverse pharmaceutical demands worldwide.

Financially, Symbiotec Pharmalab has demonstrated a consistent track record of growth. Over recent years, the company has reported steady increases in both its revenue and Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). This sustained financial performance could be a key factor for potential investors evaluating the IPO.

Opportunity for High-Risk Investors

For investors with a high-risk appetite, the Symbiotec Pharmalab IPO could present a long-term investment opportunity. The company's strong market position in a niche segment of the API market, coupled with its consistent financial growth and plans for expansion, may appeal to those looking for potential growth in the pharmaceutical sector. However, as with any IPO, especially in specialized industries, it carries inherent risks that investors should carefully consider.

The funds raised from the IPO are critical for the company's future trajectory. By addressing debt obligations, Symbiotec Pharmalab aims to strengthen its balance sheet, potentially freeing up capital for further research and development, capacity expansion, and market penetration. This could solidify its leadership in the corticosteroid and steroidal-hormone API segments and drive future revenue growth.

This report is for informational purposes only and should not be construed as investment advice.

Recommended for you
Products related to this story — compare & act
Smart picks
Mirae Asset ELSS Tax Saver Fund
Mirae Asset Mutual Fund · ELSS
14.1%
3Y CAGR
Bharat Mobility IPO
Mainboard · Auto
+20.5%
GMP
View IPO
Nippon India Small Cap Fund
Nippon India Mutual Fund · Small Cap
13.8%
3Y CAGR
GreenVolt Energy IPO
Mainboard · Renewables
+13.8%
GMP
View IPO
Parag Parikh Flexi Cap Fund
PPFAS Mutual Fund · Flexi Cap
13.5%
3Y CAGR
Axis ELSS- Tax Saver Fund
Axis Mutual Fund · ELSS
12.8%
3Y CAGR

IPO investments are subject to market risk and allotment. Read the RHP / prospectus before applying; grey-market premium (GMP) is unofficial and unreliable. Some listings may be sponsored. Not investment advice.

Frequently Asked Questions

What is the primary purpose of Symbiotec Pharmalab's IPO?

The primary purpose of Symbiotec Pharmalab's IPO is to raise ₹150 crore, which will be utilized for repaying existing debt and funding the company's operational expansion plans.

What is Symbiotec Pharmalab's market position?

Symbiotec Pharmalab holds a global leadership position in the manufacturing of corticosteroid and steroidal-hormone Active Pharmaceutical Ingredients (APIs).

How has Symbiotec Pharmalab's financial performance been recently?

Symbiotec Pharmalab has demonstrated steady revenue and EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) growth over recent years, with a significant portion of its revenue coming from international markets, particularly Europe.

Stay ahead of the market

Join the Arth Vani channels

Daily news summaries, IPO & market alerts on Telegram and WhatsApp.

Related Stories

Hindustan Coca-Cola Beverages IPO: Details Awaited for Anticipated Listing
IPOBreaking
IPOs

Hindustan Coca-Cola Beverages IPO: Details Awaited for Anticipated Listing

Hindustan Coca-Cola Beverages (HCCB), the bottling arm of Coca-Cola in India, is reportedly preparing for an initial public offering (IPO). While market buzz suggests an upcoming listing, concrete specifics like the issue size, price band, and dates are yet to be officially disclosed by the company or regulatory bodies.

2h ago·1 min readListen
Crystal Crop Protection IPO Anticipated: What Investors Should Watch For
IPOBreaking
IPOs

Crystal Crop Protection IPO Anticipated: What Investors Should Watch For

Crystal Crop Protection is expected to launch its Initial Public Offering (IPO), bringing a new opportunity for retail investors to participate in the company's growth. While specific details regarding the issue size, price band, and exact dates are yet to be officially announced, market participants are closely monitoring developments for this anticipated offering.

2h ago·2 min readListen
Haldiram Snacks Food Plans ₹10,000 Crore IPO by Late 2027
IPOBreaking
IPOs

Haldiram Snacks Food Plans ₹10,000 Crore IPO by Late 2027

Iconic Indian snacks brand Haldiram Snacks Food is reportedly planning a significant Initial Public Offering (IPO) valued at ₹10,000 crore. The company aims to launch this major equity offering by late 2027, potentially allowing retail investors to participate in one of India's most recognized food sector businesses.

2h ago·2 min readListen
Hindustan Coca-Cola IPO: Investors Await Official Details, GMP Buzz
IPO
IPOs

Hindustan Coca-Cola IPO: Investors Await Official Details, GMP Buzz

Investors are closely monitoring the potential Initial Public Offering (IPO) of Hindustan Coca-Cola, with current market discussions focused on its Grey Market Premium (GMP) and anticipated listing gains. However, official dates, price bands, and other key details are yet to be formally announced by the company or regulatory bodies.

2h ago·1 min readListen